Skip to Main Content

Author Details

Cheryl Ho
University of British Columbia
1995
115
22
PMIDPaper TitleJournal TitlePublished Year
36180762Mapping the experiences of people with advanced cancer across multiple cancer types-a scoping review.J Cancer Surviv2024
36320173Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers.J Oncol Pharm Pract2023
37623024Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression.Curr Oncol2023
37622996Real-World Clinical Outcomes for Patients with <i>EGFR</i> and <i>HER2</i> Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer.Curr Oncol2023
37076834Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults.BMC Cancer2023
36972505Response to letter to the editor: Use, response and outcomes of second line chemotherapy in patients with advanced biliary tract cancers.J Oncol Pharm Pract2023
37366885Real-World Outcomes of Stage IV NSCLC with PD-L1 â¿¥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy.Curr Oncol2023
37033344The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management.Transl Cancer Res2023
36848085Predicting the Survival of Patients With Cancer From Their Initial Oncology Consultation Document Using Natural Language Processing.JAMA Netw Open2023
34786889Effect of targeted therapy and immunotherapy on advanced nonsmall-cell lung cancer outcomes in the real world.Cancer Med2022
35651371Acute Onset of a Life-Threatening Skin Toxicity Due to Osimertinib: Severe Psoriasis Versus Toxic Epidermal Necrolysis.Cureus2022
35498385Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report.JTO Clin Res Rep2022
35367630The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space.J Mol Diagn2022
35623671Hyper-Sensitive? Targeted Therapy With a Primed Immune System.J Thorac Oncol2022
36547179Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization.Curr Oncol2022
36421338Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS â¿¥ 50%: 3 Weekly Compared to 6 Weekly Dosing.Curr Oncol2022
36455583International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic.Lancet Oncol2022
36661661Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study.Curr Oncol2022
36067447End-of-Life Health Resource Utilization for Limited English-Proficient Patients With Advanced Non-Small-Cell Lung Cancer.JCO Oncol Pract2022
35882607Cervical cancer patient reported gastrointestinal outcomes: intensity/volumetric modulated vs. 3D conformal radiation therapy.J Gynecol Oncol2022
36284134A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada.NPJ Precis Oncol2022
36185266Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer.Front Oncol2022
35216902Defining a Core Data Set for the Economic Evaluation of Precision Oncology.Value Health2022
35308690Radiation Induced Abscopal Effect in a Patient With Malignant Pleural Mesothelioma on Pembrolizumab.Cureus2022
35200536FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment.Curr Oncol2022
32865672Patient-reported psychosocial distress in adolescents and young adults with germ cell tumours.Support Care Cancer2021
33770662Discordance in PD-L1 scores on repeat testing of non-small cell lung carcinomas.Cancer Treat Res Commun2021
33493006Readiness of Healthcare Systems to Generate Real-World Evidence: Reliability of CT Radiographic End Points for Evaluation of First-Line Systemic Treatment.JCO Oncol Pract2021
33653306Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment.BMC Cancer2021
33896566Increasing Transparency in Author Contributions to Manuscripts: Enhanced Policy on Ghost and Honorary Authorships.J Thorac Oncol2021
33667719MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy.Lung Cancer2021
34820133A Canadian Study of Cisplatin Metabolomics and Nephrotoxicity (ACCENT): A Clinical Research Protocol.Can J Kidney Health Dis2021
34379128Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program.JAMA Netw Open2021
34388408Canadian consensus statement on the management of radioactive iodine-resistant differentiated thyroid cancer.Oral Oncol2021
34256112High-Ambient Air Pollution Exposure Among Never Smokers Versus Ever Smokers With Lung Cancer.J Thorac Oncol2021
33158770Patient-reported psychosocial needs and psychological distress predict survival in geriatric oncology patients.J Geriatr Oncol2021
33157383Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma.Ann Diagn Pathol2021
32949298Patient-reported outcome measures in patients undergoing radiotherapy for head and neck cancer.Support Care Cancer2021
31630293Emotional distress and psychosocial needs in patients with breast cancer in British Columbia: younger versus older adults.Breast Cancer Res Treat2020
34589962Survival Outcomes of Salvage Therapy for Local and Regionally Recurrent NSCLC.JTO Clin Res Rep2020
32000829Population-based analysis of curative therapies in stage II non-small cell lung cancer: the role of radiotherapy in medically inoperable patients.Radiat Oncol2020
31871216Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic <i>DPYD</i> structural variant.Cold Spring Harb Mol Case Stud2020
33310367Applicability of the PACIFIC trial results in patients not eligible for the PACIFIC trial: Canadian rapid consensus statement and recommendations.Cancer Treat Res Commun2020
32953487EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes.Transl Lung Cancer Res2020
32218657Biopsy on progression in patients with <i>EGFR</i> mutation-positive advanced non-small-cell lung cancer-a Canadian experience.Curr Oncol2020
32257668Treatment for Recurrent Differentiated Thyroid Cancer: A Canadian Population Based Experience.Cureus2020
32255694Distinct Features of Psychosocial Distress of Adolescents and Young Adults with Cancer Compared to Adults at Diagnosis: Patient-Reported Domains of Concern.J Adolesc Young Adult Oncol2020
31454429Intratumoral heterogeneity in programmed death-ligand 1 immunoreactivity is associated with variation in non-small cell lung carcinoma histotype.Histopathology2020
30514790Clinical outcomes after whole-genome sequencing in patients with metastatic non-small-cell lung cancer.Cold Spring Harb Mol Case Stud2019
31696009Patterns of Radiotherapy Utilization for Lung Cancer Patients with Brain Metastases: A Population-based Analysis.Cureus2019
  • 1 - 50 of 115

Recommended Authors

Andrew Warner
Western University and London Regional Cancer Program
Career Start Year 2013
Number of shared co-authors 6
Philip E Lammers
Baptist Cancer Center
Career Start Year 2013
Number of shared co-authors 0
Jyoti Malhotra
Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School
Career Start Year 2012
Number of shared co-authors 1
Marliese Alexander
Department of Pharmacy, 5Peter MacCallum Cancer Centre
Career Start Year 2011
Number of shared co-authors 0
Caroline E McCoach
UCSF Helen Diller Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 2
Chen Hu
Johns Hopkins University School of Medicine
Career Start Year 2009
Number of shared co-authors 0
Puey Ling Chia
Lee Kong Chian School of Medicine, Nanyang Technological University
Career Start Year 2009
Number of shared co-authors 3
Saiama N Waqar
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 2009
Number of shared co-authors 1
Gideon M Blumenthal
Oncology Center of Excellence
Career Start Year 2008
Number of shared co-authors 3
Bhumsuk Keam
Seoul National University Hospital
Career Start Year 2006
Number of shared co-authors 2
Edward B Garon
David Geffen School of Medicine, University of California Los Angeles
Career Start Year 2005
Number of shared co-authors 2
Daniel R Gomez
Memorial Sloan Kettering Cancer Center
Career Start Year 2005
Number of shared co-authors 5
Matthew A Gubens
University of California san francisco
Career Start Year 2003
Number of shared co-authors 2
Lecia V Sequist
Massachusetts General Hospital Cancer Center, Harvard Medical School
Career Start Year 2003
Number of shared co-authors 3
Aaron Lisberg
Jonsson Comprehensive Cancer Center, university of california los angeles
Career Start Year 2002
Number of shared co-authors 0
Gregory R Pond
Juravinski Hospital and Cancer Centre, Escarpment Cancer Research Institute
Career Start Year 2001
Number of shared co-authors 10
Drew Moghanaki
University of California Los Angeles
Career Start Year 2000
Number of shared co-authors 1
Fiona Blackhall
The University of Manchester
Career Start Year 2000
Number of shared co-authors 6
Daniel Morgensztern
Washington University School of Medicine
Career Start Year 2000
Number of shared co-authors 1
Benjamin Solomon
Peter MacCallum Cancer Centre
Career Start Year 2000
Number of shared co-authors 8
Katherine S Panageas
Memorial Sloan Kettering Cancer Center
Career Start Year 1996
Number of shared co-authors 1
Puneeth Iyengar
UT Southwestern Medical Center, Center for Human Nutrition
Career Start Year 1996
Number of shared co-authors 1
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Career Start Year 1995
Number of shared co-authors 14
Vincent A Miller
Injury Prevention Research Center, University of North Carolina
Career Start Year 1994
Number of shared co-authors 5
Gregory J Riely
Memorial Sloan Kettering Cancer Center
Career Start Year 1994
Number of shared co-authors 5
Paul Mitchell
Olivia Newton-John Cancer Research Institute
Career Start Year 1993
Number of shared co-authors 6
Jonathan W Goldman
David Geffen School of Medicine at university of california los angeles
Career Start Year 1991
Number of shared co-authors 1
Roy S Herbst
Yale School of Medicine
Career Start Year 1984
Number of shared co-authors 4
Ramaswamy Govindan
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 1981
Number of shared co-authors 8
Giuseppe Giaccone
Meyer Cancer Center
Career Start Year 1981
Number of shared co-authors 5

Collaborators

Janessa Laskin
Co-authored papers 38
Marco A Marra
University of British Columbia
Co-authored papers 9
Martin R Jones
BC Cancer Research Centre.
Co-authored papers 8
Steven J M Jones
University of British Columbia
Co-authored papers 7
Primo N Lara
University of California Davis Comprehensive Cancer Center
Co-authored papers 6
Laurel A Beckett
University of California davis
Co-authored papers 5
Andrew J Mungall
Co-authored papers 5
Yussanne Ma
Co-authored papers 5
Paul Wheatley-Price
The Ottawa Hospital Research Institute
Co-authored papers 4
Richard A Moore
Co-authored papers 4
Eric Winquist
Schulich School of Medicine and Dentistry, University of Western Ontario
Co-authored papers 4
Ian Bosdet
University of British Columbia
Co-authored papers 4
Frances A Shepherd
University Health Network, Princess Margaret Cancer Centre
Co-authored papers 3
Katayoon Kasaian
Ontario Institute for Cancer Research
Co-authored papers 3
Kasmintan A Schrader
University of British Columbia
Co-authored papers 3
Carolyn Ch'ng
GenomeDx Biosciences Inc.
Co-authored papers 3
Caralyn Reisle
University of British Columbia
Co-authored papers 3
Jacqueline E Schein
Canada British Columbia Cancer Research Centre, University of British Columbia
Co-authored papers 2
Geoffrey Liu
The Princess Margaret Cancer Centre/University of Toronto
Co-authored papers 2
Yongjun Zhao
Canada British Columbia Cancer Research Centre, University of British Columbia
Co-authored papers 2
Shahrad Rod Rassekh
British Columbia Children's Hospital, The University of British Columbia
Co-authored papers 2
Steve E Kalloger
University of British Columbia
Co-authored papers 2
Tania Bubela
Simon Fraser University
Co-authored papers 1
Giles Lajoie
Schulich School of Medicine & Dentistry, Western University
Co-authored papers 1
Paul C Nathan
The Hospital for Sick Children, University of Toronto
Co-authored papers 1
Melika Bonakdar
Co-authored papers 1
Sharon Abish
McGill University
Co-authored papers 1
Helen J Ross
Mayo Clinic
Co-authored papers 1
Anshika Jain
University of Toronto
Co-authored papers 1
Eitan Prisman
University of British Columbia
Co-authored papers 1
Release 1.2